Table 1. Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of non-cancer indications.
| Sponsoring company | INN or code name | Molecular type | Target(s) | Current phase | Phase 2/3 or 3 indications |
|---|---|---|---|---|---|
| Amgen |
AMG 145 |
Human IgG2 |
PCSK-9 |
Phase 2/3 |
High cholesterol |
| Regeneron; Sanofi |
Alirocumab, REGN-727, SAR236553 |
Human IgG1 |
PCSK-9 |
Phase 3 |
High cholesterol; acute coronary syndrome |
| Amgen |
Romosozumab |
Humanized IgG2 |
Sclerostin |
Phase 3 |
Postmenopausal osteoporosis |
| Merck |
Actoxumab + bezlotoxumab (MK-3415A) |
Human IgG1 |
C. difficile enterotoxin A and B |
Phase 3 |
C. difficile Infection |
| Xoma; Servier |
Gevokizumab |
Humanized IgG2 |
IL-1 β |
Phase 3 |
Non-infectious uveitis |
| GlaxoSmithKline |
Mepolizumab |
Humanized IgG1 |
IL-5 |
Phase 3 |
Asthma; hypereosinophilic syndrome; COPD with eosinophilic bronchitis |
| Teva |
Reslizumab |
Humanized IgG4 |
IL-5 |
Phase 3 |
Eosinophilic asthma |
| Janssen Research & Development LLC |
Sirukumab |
Human IgG1 |
IL-6 |
Phase 3 |
Rheumatoid arthritis |
| Regeneron; Sanofi |
Sarilumab, SAR153191, REGN88 |
Human IgG1 |
IL-6R subunit α |
Phase 3 |
Rheumatoid arthritis |
| Genentech |
Lebrikizumab |
Humanized IgG4 |
IL-13 |
Phase 3 |
Asthma |
| Eli Lilly and Co. |
Ixekizumab (LY2439821) |
Humanized IgG4 |
IL-17a |
Phase 3 |
Psoriasis |
| Novartis Pharmaceuticals |
Secukinumab |
Human IgG1 |
IL-17a |
Phase 3 |
Rheumatoid or psoriatic arthritis; ankylosing spondylitis; psoriasis |
| Millennium Pharmaceuticals |
Vedolizumab |
Humanized IgG1 |
alpha4/beta7 integrin |
Phase 3 |
Ulcerative colitis; Crohn disease |
| Eli Lilly and Co. |
Tabalumab, LY2127399 |
Human IgG4 |
BLyS |
Phase 3 |
SLE; rheumatoid arthritis, MM |
| Biocon |
Itolizumab |
Humanized IgG1 |
CD6 |
Phase 3 |
Plaque psoriasis |
| Genentech |
Ocrelizumab |
Humanized IgG1 |
CD20 |
Phase 3 |
Multiple sclerosis |
| UCB |
Epratuzumab |
Humanized IgG1 |
CD22 |
Phase 3 |
SLE |
| Hoffmann-LaRoche |
Gantenerumab |
Human IgG1 |
Amyloid beta |
Phase 3 |
Alzheimer disease |
| Eli Lilly and Co. | Solanezumab | Humanized IgG1 | Amyloid beta | Phase 3 | Alzheimer disease |
Table compiled from information available as of November 15, 2012. IL, interleukin ; MM, multiple myeloma ; PCSK9, proprotein convertase subtilisin/kexin type; SLE, systemic lupus erythematosus